Error loading player: No playable sources found

Bridging Session - Leveraging Contract Organization Networks to Enhance Patient Access in Lower and Middle-Income Countries

Date
January 29, 2025
This product is not available for individual purchase, but it is available as part of the following products:

Access to advanced medical treatments remains a significant challenge in lower and middle-income countries (LMICs), often due to barriers in manufacturing, distribution, and regulatory complexities. This plenary session explores how Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) can play a pivotal role in bridging these gaps and enhancing patient access to essential therapies in LMICs. 

CMOs and CDMOs are instrumental in the pharmaceutical supply chain, providing expertise in the development, production, and scaling of medicines. Their extensive networks and operational capabilities offer unique opportunities to address the access disparities faced by LMICs. The session will delve into strategies for leveraging these networks to overcome common obstacles, such as high production costs, limited local manufacturing infrastructure, and regulatory hurdles. 

Key topics will include: 

1. Optimizing Production and Distribution: Exploring how CMOs and CDMOs can help reduce costs and streamline production processes to make medicines more affordable and accessible. Case studies will highlight successful collaborations that have led to the establishment of local manufacturing facilities and improved distribution channels in LMICs. 

2. Regulatory and Quality Assurance: Addressing the challenges related to meeting diverse regulatory standards and ensuring consistent quality across different markets. Discussion will focus on best practices for navigating regulatory environments and implementing robust quality assurance measures to ensure compliance and safety. 

3. Innovative Partnerships and Collaborations: Examining partnerships between CMOs, CDMOs, governments, and non-governmental organizations (NGOs) that have facilitated patient access to life-saving treatments. The session will showcase examples of successful models and explore opportunities for scaling these approaches. 

4. Capacity Building and Knowledge Transfer: Highlighting initiatives that focus on building local capabilities through knowledge transfer and training programs. This will cover how CMOs and CDMOs can support capacity building efforts to empower local stakeholders and enhance self-sufficiency in drug production. 

By the end of the session, participants will gain insights into effective strategies and actionable frameworks for leveraging the strengths of CMOs and CDMOs to improve healthcare outcomes in LMICs. The discussion will emphasize the importance of collaborative efforts and innovative solutions to ensure that more patients in underserved regions receive timely access to essential medicines and treatments. 


Session Speakers: 


Accelerating Access to Essential Medicines by Maximizing the Benefits of Contract Manufacturing

Ken KentGilead Sciences, Inc.


Virtual Presentation

Boitumelo (Tumi) Semete-Makokotlela, South African Health Products


MRNA Technology Transfer Programme: Towards a Better Prepared Global South

Antonio Grilo, Medicines Patent Pool (MPP) 



Additional Panelists:


Dean Smith, Health Canada


Related Products

Thumbnail for Parallel Session 6B: The Critical Need to Protect the Horseshoe Crab: Initiatives from Industry, Suppliers and Regulators to Replace the LAL Assay
Parallel Session 6B: The Critical Need to Protect the Horseshoe Crab: Initiatives from Industry, Suppliers and Regulators to Replace the LAL Assay
The pharmaceutical industry is increasingly viewed as a key sector systemically important in reversing nature loss.     One of the sector’s key dependencies is on the horseshoe crab , a species that is vital to marine ecosystems only located in a few locations globally…
Thumbnail for Parallel Session 5A - Integrated Control Strategy for Combination Products
Parallel Session 5A - Integrated Control Strategy for Combination Products
Drug-device combination products such as prefilled syringes, autoinjectors, etc. can play an important role to ensure patient convenience, compliance, and enhance therapeutic impact of the drug…
Thumbnail for Parallel Session 2A - Science vs the Fear Factor: Alternative Potency Assays for Recombinant Biologics and Vaccines
Parallel Session 2A - Science vs the Fear Factor: Alternative Potency Assays for Recombinant Biologics and Vaccines
Potency analytical control strategies are critical to support biopharmaceutical drug and vaccine development throughout the product lifecycle…